-transparent.png){kind=logo}
During A-ALL induction treatment, HD-ara-C (2.5 g/m2 IV, day 1), does not produce any beneficial effect, whereas the hematologic toxicity is increased. A 3-month consolidation phase comprising intermittent MTX, ara-C and 6-TG is not significantly affecting either DFI or survival in A-ALL. The association of HD-ara-C and m-AMSA appears to be a promising salvage therapy for the 20% A-ALL refractory to first induction therapy. The quality of autologous bone marrow graft, harvested after HD-ara-C, seems to be impaired as suggested by a delayed recovery of PMN and platelets. HD-ara-C (3 g/m2 X N) given the days before cyclophosphamide and TBI as conditioning treatment for BMT does not seem to induce prohibitory additional toxicity. Whether HD-ara-C was given four to six times or eight to 12 times gave no significant difference in early toxicity.
P Stryckmans, and
T De Witte, and
N Bitar, and
J P Marie, and
S Suciu, and
G Solbu, and
L Debusscher, and
J Bury, and
M Peetermans, and
J M Andrien
January 1981,
Cancer clinical trials,
P Stryckmans, and
T De Witte, and
N Bitar, and
J P Marie, and
S Suciu, and
G Solbu, and
L Debusscher, and
J Bury, and
M Peetermans, and
J M Andrien
June 1987,
Seminars in oncology,
P Stryckmans, and
T De Witte, and
N Bitar, and
J P Marie, and
S Suciu, and
G Solbu, and
L Debusscher, and
J Bury, and
M Peetermans, and
J M Andrien
January 1977,
Cancer treatment reports,
P Stryckmans, and
T De Witte, and
N Bitar, and
J P Marie, and
S Suciu, and
G Solbu, and
L Debusscher, and
J Bury, and
M Peetermans, and
J M Andrien
April 2012,
Mymensingh medical journal : MMJ,
P Stryckmans, and
T De Witte, and
N Bitar, and
J P Marie, and
S Suciu, and
G Solbu, and
L Debusscher, and
J Bury, and
M Peetermans, and
J M Andrien
September 1978,
Cancer treatment reports,
P Stryckmans, and
T De Witte, and
N Bitar, and
J P Marie, and
S Suciu, and
G Solbu, and
L Debusscher, and
J Bury, and
M Peetermans, and
J M Andrien
January 2014,
Medicinski pregled,
P Stryckmans, and
T De Witte, and
N Bitar, and
J P Marie, and
S Suciu, and
G Solbu, and
L Debusscher, and
J Bury, and
M Peetermans, and
J M Andrien
April 1989,
The American journal of medicine,
P Stryckmans, and
T De Witte, and
N Bitar, and
J P Marie, and
S Suciu, and
G Solbu, and
L Debusscher, and
J Bury, and
M Peetermans, and
J M Andrien
December 1991,
American journal of hematology,
P Stryckmans, and
T De Witte, and
N Bitar, and
J P Marie, and
S Suciu, and
G Solbu, and
L Debusscher, and
J Bury, and
M Peetermans, and
J M Andrien
December 2001,
Cancer treatment reviews,
P Stryckmans, and
T De Witte, and
N Bitar, and
J P Marie, and
S Suciu, and
G Solbu, and
L Debusscher, and
J Bury, and
M Peetermans, and
J M Andrien
January 1979,
Cancer treatment reports,
